In today’s briefing:
- Quiddity Leaderboard ASX Sep25: Update with New Important Market Consultation Implications
- Innovent Biologics Placement – Second for the Month, Stock Has Doubled but Momentum Is Strong
- An Updated Progress on the Tender Offer and Delisting of Viol By VIG Partners
- I’d Stay Far Away from UnitedHealth.
- EVAX: New Vaccine Added to Pipeline
- Acadia Healthcare: Focus on Supplemental Payments to Bolster Financial Performance & Maintain A Stable Cash Flow!
- MIRA: New Data Shows Promise from New Acquisition
- Pre-IPO Nanjing Leads Biolabs (PHIP Updates) – Thoughts on the Valuation and the Outlook
- QuidelOrtho Corporation Is Executing A Billion-Dollar Manufacturing Overhaul; What Is The Expected Revenue Impact?
- Bayer AG has reported its first quarter results for 2025
Quiddity Leaderboard ASX Sep25: Update with New Important Market Consultation Implications
- Couple of days ago, I published my index change expectations for the ASX index family in the run up to the September 2025 index review (link).
- After market close yesterday, the index provider announced a market consultation on potential changes to the index methodology which could become effective during the September review if it gets approved.
- This is a short insight with our revised ranks for the potential ADDs and DELs assuming the market consultation gets approved.
Innovent Biologics Placement – Second for the Month, Stock Has Doubled but Momentum Is Strong
- Innovent Biologics Inc (1801 HK) aims to raise around US$500m for R&D and marketing.
- The company has undertaken a number of deals in the past, with the overall results being mixed but recent deals have done well.
- In this note, we will talk about the deal dynamics and run the deal through our ECM framework.
An Updated Progress on the Tender Offer and Delisting of Viol By VIG Partners
- This insight provides an updated progress on the tender offer and delisting of VIOL (335890 KS). The tender offer period lasts from 18 June to 7 July 2025.
- Through this tender offer, VIG Partners plans to acquire full management rights of Viol and also take it private.
- If the number of shares offered for the tender offer reaches the maximum target, SPC will secure a 98.84% stake in Viol.
I’d Stay Far Away from UnitedHealth.
Much of UnitedHealth’s business is just freeriding the US healthcare system.
To some extent it could even be called parasitic. 40% of its revenues come from government programs.
The most important one is Medicare Advantage (MA), which was originally designed to lower costs through the use of private carriers and their competition.
EVAX: New Vaccine Added to Pipeline
- EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.
- The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.
- The company announced its AI technology has identified a new novel vaccine target to combat a major bacterial infection impacting hundreds of millions of people around the world.
Acadia Healthcare: Focus on Supplemental Payments to Bolster Financial Performance & Maintain A Stable Cash Flow!
- Acadia Healthcare Company, Inc. reported its first quarter financial results for 2025, demonstrating a balanced mix of strategic growth and operational challenges.
- The company’s revenue for the quarter reached $770.5 million, aligning well with their expectations.
- Adjusted EBITDA was $134.2 million, reaching the higher end of the forecasted range.
MIRA: New Data Shows Promise from New Acquisition
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
Pre-IPO Nanjing Leads Biolabs (PHIP Updates) – Thoughts on the Valuation and the Outlook
- Even if the first indication of LBL-024 is approved, it wouldn’t bring significant performance growth due to small market size for EP-NEC. Commercialization prospects of LBL-007 are also not optimistic.
- Leads Biolabs’ CD3 pipelines would have higher hope to be successful. However, early-stage investors transferred their equity at a discount before IPO, which may reflect their concerns about the prospects.
- Comfortable valuation is RMB3-4bn, which provides investors with a greater margin of safety.Especially in the context of current bull market of innovative drugs, biotech valuation has been full of bubble
QuidelOrtho Corporation Is Executing A Billion-Dollar Manufacturing Overhaul; What Is The Expected Revenue Impact?
- QuidelOrtho’s latest earnings provides insight into the company’s performance and strategic direction.
- For the first quarter of 2025, QuidelOrtho achieved total reported revenue of $693 million, experiencing a decline from $711 million in the previous year.
- This decline is primarily attributed to reduced revenue from COVID-19 testing and the planned wind-down of the Donor Screening business.
Bayer AG has reported its first quarter results for 2025
- Bayer AG has reported its first quarter results for 2025, revealing a mixed performance across its business divisions amidst challenging geopolitical and economic conditions.
- The company’s overall sales remained flat year-over-year, in line with its guidance range of -3% to +1%.
- In the Crop Science division, sales declined by 3%, primarily due to regulatory impacts affecting high-margin sales, leading to a lower EBITDA margin compared to the previous year.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
